Standout Papers

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nas... 2017 2026 2020 2023 293
  1. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study (2017)
    Chiun Hsu, Se‐Hoon Lee et al. Journal of Clinical Oncology

Immediate Impact

7 by Nobel laureates 8 from Science/Nature 64 standout
Sub-graph 1 of 21

Citing Papers

Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
2024 Standout
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
2 intermediate papers

Works of Samuel Ejadi being referenced

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
2017
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal
2017
and 3 more

Author Peers

Author Last Decade Papers Cites
Samuel Ejadi 1044 494 387 431 34 1.6k
Christine K. Gause 1532 513 370 599 38 1.9k
Alexis Desrichard 1084 362 633 741 21 1.9k
Sumita Trivedi 828 281 408 574 33 1.5k
Fernando Concha‐Benavente 1061 272 262 678 31 1.4k
Richard Lubin 1128 229 612 381 24 1.8k
Luc Bron 880 260 497 176 30 1.7k
You Hong Fan 828 220 784 212 24 1.7k
Ayman Oweida 675 237 329 414 44 1.3k
Eirini Pectasides 603 378 598 100 49 1.8k
A. K. El-Naggar 695 162 692 276 24 1.5k

All Works

Loading papers...

Rankless by CCL
2026